|
1
|
Elshan NGRD, Jayasundera T, Weber CS, Lynch RM, Mash EA. Development of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptor. Bioorg Med Chem 2015; 23:1841-8. [PMID: 25769518 PMCID: PMC4380538 DOI: 10.1016/j.bmc.2015.02.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2015] [Revised: 02/06/2015] [Accepted: 02/16/2015] [Indexed: 10/23/2022]
Abstract
The synthesis, characterization, and use of Eu-DTPA-PEGO-Trp-Nle-Asp-Phe-NH2 (Eu-DTPA-PEGO-CCK4), a luminescent probe targeted to cholecystokinin 2 receptor (CCK2R, aka CCKBR), are described. The probe was prepared by solid phase synthesis. A Kd value of 17±2nM was determined by means of saturation binding assays using HEK-293 cells that overexpress CCK2R. The probe was then used in competitive binding assays against Ac-CCK4 and three new trivalent CCK4 compounds. Repeatable and reproducible binding assay results were obtained. Given its ease of synthesis, purification, receptor binding properties, and utility in competitive binding assays, Eu-DTPA-PEGO-CCK4 could become a standard tool for high-throughput screening of compounds in development targeted to cholecystokinin receptors.
Collapse
Affiliation(s)
- N G R Dayan Elshan
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721-0041, USA
| | | | - Craig S Weber
- Department of Physiology, University of Arizona, Tucson, AZ 85724-5051, USA
| | - Ronald M Lynch
- Department of Physiology, University of Arizona, Tucson, AZ 85724-5051, USA; The Bio5 Institute, University of Arizona, Tucson, AZ 85721-0240, USA
| | - Eugene A Mash
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721-0041, USA.
| |
Collapse
|
|
2
|
Shabanpoor F, Separovic F, Wade JD. General method for selective labelling of double-chain cysteine-rich peptides with a lanthanide chelate via solid-phase synthesis. J Pept Sci 2011; 17:169-73. [PMID: 21308873 DOI: 10.1002/psc.1307] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2010] [Revised: 08/27/2010] [Accepted: 08/27/2010] [Indexed: 11/12/2022]
Abstract
The use of lanthanides in preference to radioisotopes as probes for various biological assays has gained enormous popularity. The introduction of lanthanide chelates to peptides/proteins can be carried out either in solution using a commercially available labelling kit or by solid-phase peptide synthesis using an appropriate lanthanide chelate. Herein, a detailed protocol for the latter is provided for the labelling of peptides or small proteins with diethylenetriamine-N, N, N″, N″-tetra-tert-butyl acetate-N'-acetic acid (DTPA) chelate or other similar chelates on a solid support using a chimeric insulin-like peptide composed of human insulin-like peptide 5 (INSL5) A-chain and relaxin-3 B-chain as a model peptide. Copyright © 2011 European Peptide Society and John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Fazel Shabanpoor
- Howard Florey Institute, University of Melbourne, Victoria 3010, Australia
| | | | | |
Collapse
|
|
3
|
Shabanpoor F, Hughes RA, Bathgate RAD, Zhang S, Scanlon DB, Lin F, Hossain MA, Separovic F, Wade JD. Solid-Phase Synthesis of Europium-Labeled Human INSL3 as a Novel Probe for the Study of Ligand−Receptor Interactions. Bioconjug Chem 2008; 19:1456-63. [DOI: 10.1021/bc800127p] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Fazel Shabanpoor
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | - Richard A. Hughes
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | - Ross A. D. Bathgate
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | - Suode Zhang
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | - Denis B. Scanlon
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | - Feng Lin
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | - Mohammed Akhter Hossain
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | - Frances Separovic
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| | - John D. Wade
- Howard Florey Institute, School of Chemistry, Department of Pharmacology, Department of Biochemistry and Molecular Biology, and Bio21 Institute, The University of Melbourne, Victoria 3010, Australia
| |
Collapse
|